Hims and Hers Health shakes weight loss market with cheap compounded Wegovy pill
Hims and Hers Health introduced a $49 monthly compounded version of the Wegovy pill today. The move triggered a drop in shares for Novo Nordisk and Eli Lilly.
Insights:
Hims & Hers Health, Inc. announced today that it will begin offering compounded versions of the Wegovy (Novo Nordisk's semaglutide product) pill at an introductory price of $49 per month. The announcement prompted an immediate market reaction as shares of Novo Nordisk A/S and Eli Lilly and Company fell. Investors view the introduction of lower-cost compounded alternatives as a potential source of pricing and margin pressure for branded GLP-1 drugs in the increasingly competitive weight-loss sector.
The move by Hims & Hers Health, Inc. comes shortly after the release of earnings and financial outlooks from both Novo Nordisk A/S and Eli Lilly and Company , raising near-term investor concern. Analysts such as Karen Andersen karen andersen and Michael Cherny michael cherny are closely watching how these developments affect the oral GLP-1 / weight-loss drug market. Christian Moore christian moore and other industry experts have noted that the availability of significantly cheaper alternatives could shift the market dynamics for established pharmaceutical leaders.
